Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2

Brown et al report a novel plasmid-mediated carbapenemase (ARI-2) from a multiresistant clinical isolate of Acinetobacter baumannii from Argentina.

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 351; no. 9097; pp. 186 - 187
Main Authors:	Brown, Susan, Bantar, Carlos, Young, Hilary-Kay, Amyes, Sebastian GB
Format:	Journal Article
Language:	English
Published:	London Elsevier Ltd 17-01-1998 Lancet Elsevier Limited
Subjects:	Acinetobacter - drug effects Acinetobacter - enzymology Acinetobacter - genetics Acinetobacter Infections - drug therapy Antibacterial agents Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Bacteria Bacterial Proteins beta-Lactam Resistance beta-Lactamases - isolation & purification beta-Lactamases - pharmacology Biological and medical sciences Clinical trials Drug therapy Humans Imipenem - therapeutic use Infections Medical sciences Metalloproteins - isolation & purification Metalloproteins - pharmacology Pharmacology. Drug treatments Plasmids Thienamycins - therapeutic use Human Treatment efficiency Neisseriaceae Chemical mediator Infection Plasmid Acinetobacter baumannii Antibiotic Carbapenem derivatives Chemotherapy Microorganism resistance Treatment Bacteriosis Bacteria Micrococcales
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Brown et al report a novel plasmid-mediated carbapenemase (ARI-2) from a multiresistant clinical isolate of Acinetobacter baumannii from Argentina.
Bibliography:	SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Correspondence-1
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(05)78210-6